Whilst Takeda may not have an interest in DMX200 in particular given their focus is elsewhere, they certainly have an interest, knowledge and appreciation for the underlying drug discovery platform owned by Dimerix, which is where many of us here believe the true value lies.
It was only in 2016 that Takeda actually presented work using Dimerix' platform:
http://dimerix.com/wp-content/uploads/1628254.pdf
Whilst Takeda may not have an interest in DMX200 in particular...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.0¢ |
Change
0.040(8.89%) |
Mkt cap ! $269.6M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 50.5¢ | 46.0¢ | $2.255M | 4.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.5¢ | 21052 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |